Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is one of the stocks under $1 that will explode. Sangamo Therapeutics, Inc.’s ...

RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third ...

Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to ...

Good morning, and welcome to Sangamo Therapeutics Third Quarter 2025 Conference Call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your ...

RICHMOND, Calif. (AP) — RICHMOND, Calif. (AP) — Sangamo Therapeutics Inc. (SGMO) on Thursday reported a loss of $34.9 million in its third quarter. The Richmond, California-based company said it had a ...

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic ...

Sangamo Therapeutics (SGMO) added ~9% in the premarket on Friday after the gene therapy developer said that the U.S. FDA accepted its request for a rolling submission and review of its marketing ...

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) ...

Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.11 EPS, expectations were $-0.03. Operator: Good morning, and welcome to Sangamo Therapeutics Third Quarter 2025 ...